

Cumulative Index
Psychopharmacology Bulletin
A. Contents Index
Vol. 28, No. 1—1992

**ANNUAL NCDEU MEETING (1991)—
 SELECTED PROCEEDINGS—**

**The Current Impact of Neuroscience
 on Psychotropic Drug Discovery and
 Development**

- 3** Serotonin Neuroscience Discoveries Usher
 in a New Era of Novel Drug Therapies for
 Psychiatry—*Stephen M. Stahl*

**Psychopharmacologic Treatment of
 Cocaine Dependence**

- 11** Introduction—*Jack D. Blaine and Walter
 Ling*
- 15** Buprenorphine for Cocaine and Opiate
 Dependence—*Thomas R. Kosten, Marc I.
 Rosen, Richard Schottenfeld, and Douglas
 Ziedonis*
- 21** A Pilot Trial of Gepirone vs. Placebo in
 the Treatment of Cocaine Dependency—
*Stephen W. Jenkins, Nancy A. Warfield,
 Jack D. Blaine, James Cornish,
 Walter Ling, Marc I. Rosen, Donald
 Wesson, and Douglas Ziedonis*

**Secondary Depression: Definition
 and Treatment**

- 27** Definitions of Secondary Depression:
 Effects on Comorbidity and Outcome in
 Anxiety Disorders—*Karla Moras and
 David Barlow*

NCDEU Updates

- 35** Modern Cardiovascular Standards for
 Psychotropic Drugs—*Steven P. Roose*
- 45** Monoamine Oxidase Inhibitors: Reversible
 and Irreversible—*Matthew V. Rudorfer*

**Developments in Treatment of
 Alzheimer's Disease**

- 59** Introduction—*Barry D. Lebowitz*
- 61** Effects of Phosphatidylserine in Alz-
 heimer's Disease—*Thomas Crook, William
 Petric, Charles Wells, and Danilo Casadei
 Massari*
- 67** Noradrenergic Intervention in Alzheimer's
 Disease—*Thomas Crook, Elliot Wilner,
 Anita Rothwell, Donna Winterling, and
 William McEntee*
- 71** Non-Neuroleptic Treatment of Behavioral
 Symptoms and Agitation in Alzheimer's
 Disease and Other Dementia—*Lon S.
 Schneider and Paul B. Sobin*

**Poster Summaries and Free
 Communications**

- 81** Incidence and Correlates of Acute Extra-
 pyramidal Symptoms in First Episode of
 Schizophrenia—*Miranda H. Chakos,
 David I. Mayerhoff, Antony D. Loebel,
 Jose Ma. J. Alvir, and Jeffrey A.
 Lieberman*
- 87** High Incidence of Tardive Dyskinesia in
 Older Outpatients on Low Doses of Neuro-
 leptics—*M. Jacquelyn Harris, Diane
 Panton, Michael P. Caligiuri, Alice J.
 Krull, Tram K. Tran-Johnson, and Dilip
 V. Jeste*

- 93** Disclosure of Tardive Dyskinesia: Effect of Written Policy on Risk Disclosure—*Nancy J. Kennedy and Jill S. Sanborn*

- 101** Plasma Prolactin and Homovanillic Acid as Markers for Psychopathology and Abnormal Movements After Neuroleptic Dose Decrease—*John W. Newcomer, Sherry J. Riney, Sophia Vinogradov, and John G. Csernansky*

- 109** Buprenorphine: An Alternative to Methadone for Heroin Dependence Treatment—*Richard B. Resnick, Marc Galanter, Colette Pycha, Alise Cohen, Patricia Grandison, and Noel Flood*

- B1** Psychopharmacology—A Recurring Bibliography

Vol. 28, No. 2—1992

NCDEU POSTERS AND FREE COMMUNICATIONS

- 117** Cognitive Behavior Therapy and Relapse of Nonbipolar Depression: Parallels with Pharmacotherapy—*Michael E. Thase and Anne D. Simons*
- 123** Cognitive-Behavioral Therapy for Benzodiazepine Discontinuation in Panic Disorder Patients—*Michael W. Otto, Mark H. Pollack, Samantha Meltzer-Brody, and Jerrold F. Rosenbaum*
- 131** Pharmacotherapy Observed in a Large Prospective Longitudinal Study on Anxiety Disorders—*Kimberly A. Yonkers, James M. Ellison, David M. Shera, Lisa A. Pratt, Linda M. Langford, Jonathan O. Cole, Kerrin White, Philip W. Lavori, and Martin B. Keller*
- 139** The Effect of Paroxetine on Anxiety and Agitation Associated With Depression—*David Sheehan, Geoffrey C. Dunbar, and Diane L. Fuell*
- 145** Fluoxetine for Trichotillomania: An Open Clinical Trial—*Lorrin M. Koran, Alan Ringold, and William Hewlett*
- 151** The Efficacy of Psychotropic Drugs: Implications for Power Analysis—*John M. Davis, Philip G. Janicak, Zhenguy Wang, Robert D. Gibbons, and Rajiv P. Sharma*
- 157** Predictors of Placebo Response: A Retrospective Analysis—*Charles S. Wilcox, Jay B. Cohn, Robert D. Linden, Jon F. Heiser, Peter B. Lucas, DeAnn L. Morgan, and Don DeFrancisco*
- 163** Debrisoquine Hydroxylation Phenotyping in Geriatric Psychopharmacology—*Bruce G. Pollock, James M. Perel, Linda P. Altieri, Margaret Kirshner, Amy L. Fasiczka, Patricia R. Houck, and Charles F. Reynolds III*
- 169** Low Dose Oral Haloperidol and Blood Levels in Alzheimer's Disease: A Preliminary Study—*D.P. Devanand, Thomas Cooper, Harold A. Sackeim, Elena Taurke, and Richard Mayeux*
- 175** Blocking the CA^{2+} -Activated Cytotoxic Mechanisms of Cholinergic Neuronal Death: A Novel Treatment Strategy for Alzheimer's Disease—*Roland J. Branconnier, Maureen E. Branconnier, Thomas M. Walshe, Carole McCarthy, and Patti-Ann Morse*
- 183** Haloperidol in Schizophrenic Children: Early Findings From a Study in Progress—*Elizabeth K. Spencer, Vivian Kafantaris, Maria V. Padron-Gayol, Carl R. Rosenberg, and Magda Campbell*
- 187** Pimozide in Austistic Children—*Monique Ernst, Harry J. Magee, Nilda M. Gonzalez, Joseph J. Locascio, Carl R. Rosenberg, and Magda Campbell*
- 193** Carbamazepine in Hospitalized Aggressive Conduct Disorder Children: An Open Pilot Study—*Vivian Kafantaris, Magda Campbell, Maria V. Padron-Gayol, Arthur M. Small, Joseph J. Locascio, and Carl R. Rosenberg*
- 201** Profile of a Sample of Subjects Admitted to an Acute Care Psychiatric Facility with Manic Symptoms—*Patricia A. Marken, Steven W. Stanislav, Sylvia Lacombe, Chris Pierce, Rob Hornstra, and Roger W. Sommi*

207 Effects of Nitrous Oxide on Psychological Performance—*Brian Tiplady, W.A. Sinclair, and L.M.M. Morrison*

213 Risperidone: Clinical Safety and Efficacy in Schizophrenia—*Richard L. Borison, Ananda P. Pathiraja, Bruce I. Diamond, and Richard C. Meibach*

**B1 Psychopharmacology—A
Recurring Bibliography**

Vol. 28, No. 3—1992

ACNP Selected Proceedings

Maximizing the Effects of Psychotropic Medications for Schizophrenia and Mood Disorder

- 221** Introduction—Ira D. Glick
- 223** Medication and Family Therapy for Schizophrenia and Mood Disorder—Ira D. Glick
- 227** Biologic, Pharmacologic, and Psychosocial Factors Influencing Response to Neuroleptics—John M. Kane
- 231** Relationship of Pharmacologic Compliance to Long-Term Prophylaxis in Recurrent Depression—Ellen Frank, James M. Perel, Alan G. Mallinger, Michael E. Thase, and David J. Kupfer
- 237** Psychosocial Strategies for Maximizing the Effects of Psychotropic Medications for Schizophrenia and Mood Disorder—Michael J. Goldstein
- 241** Acquisition and Retention of Skills Training Methods in Chronic Schizophrenic Outpatients—William C. Wirshing, Stephen R. Marder, Thad Eckman, Robert P. Liberman, and Jim Mintz

Other Selected Proceedings

- 247** Antigluco-corticoid Strategies in Hypercortisolemic States—Owen M. Wolkowitz, Victor I. Reus, Francesca Manfredi, Jonathan Ingbar, and Louann Brizendine
- 253** Are Patients Who Are Intolerant to One SSRI Intolerant to Another?—Walter A. Brown and Wilma Harrison

- 257** Effectiveness in Psychiatric Care: IV. Achieving Effective Medication Management for Major Affective Disorder—Ira D. Glick, Lorenzo Burti, Koji Suzuki, and Michael Sacks
- 261** Neuroanatomical Circuits in Depression: Implications for Treatment Mechanisms—Wayne C. Drevets and Marcus E. Raichle
- 275** Effects of Amfonelic Acid and GBR 12909 on the Haloperidol- and Clozapine-Induced Activation of Dopamine Neurons—Gary A. Gudelsky, E. Ewanzani Nwajei, Kristen Defife, and J. Frank Nash
- 281** Tardive Dyskinesia and Diabetes Mellitus—Linda Ganzini, Daniel E. Casey, William F. Hoffman, and Ronald T. Heintz
- 287** Transient Neutropenia Induced by Clozapine—Martina Hummer, Martin Kurz, Christian Barnas, and W. Wolfgang Fleischhacker
- 291** Benzodiazepine Augmentation of Neuroleptics in Treatment-Resistant Schizophrenia—Owen M. Wolkowitz, Neil Turetsky, Victor I. Reus, and William A. Hargreaves
- 297** Effect of Anticholinergics on Positive and Negative Symptoms in Schizophrenia—Rajiv Tandon, John R. DeQuardo, JoAnn Goodson, Nancy A. Mann, and John F. Greden
- 303** Continuation Treatment With Adjunctive Imipramine in Schizophrenia—Samuel G. Siris, Paul C. Bermanzohn, Susan E. Mason, Mitchell A. Shuwall, and Mary Anne R. Aseniero

- 309** Adjunctive Desipramine in the Treatment of Cocaine Abusing Schizophrenics—*Douglas Ziedonis, Teresa Richardson, Edward Lee, Ismene Petrakis, and Thomas Kosten*

- 315** The Convergent Validity of the Drug Impairment Rating Scale for Cocaine—*James A. Halikas, Ross D. Crosby, and Sean M. Nugent*

- 319** Side Effects Associated With Lithium and Placebo Administration in Aggressive Children—*Raul R. Silva, Magda Campbell, Robert R. Golden, Arthur M. Small, Caroly S. Pataki, and Carl R. Rosenberg*

**B1 Psychopharmacology—A
Recurring Bibliography**

Vol. 28, No. 4—1992

Special Feature: Neuropsychological Factors in Mental Disorders and Their Treatments

- 331** Measurement and Interpretation of Changes in Memory in Response to Drug Treatments—*Herbert Weingartner, Michael Eckardt, Susan Molchan, Trey Sunderland, and Owen Wolkowitz*
- 341** Toward a Neuropsychology of Memory in Schizophrenia—*Barbara L. Schwartz, Richard B. Rosse, and Stephen I. Deutsch*
- 353** Antipsychotic Medication Effects on Neuropsychological Functions—*Robert M. Bilder, Elihu Turkel, Lauren Lipschutz-Broch, and Jeffrey A. Lieberman*
- 367** Remediation of Neuropsychological Deficits in Psychiatric Populations: Rationale and Methodological Considerations—*Judith Jaeger, Stefanie Berns, Angela Tigner, and Estelle Douglas*
- 391** Mental Status Testing in Elderly Hispanic Populations: Special Concerns—*Roderick K. Mahurin, David V. Espino, and Erin B. Holifield*
- 401** Cognitive Deficits in Delirium: Assessment Over Time—*Connie Dessonville Hill, Emile Risby, and Neal Morgan*
- 409** Pharmacological Treatment of the Cognitive Side Effects of ECT: A Review—*Richard B. Krueger, Harold A. Sackeim, and Elkan R. Gamzu*
- 425** Reliability and Clinical Concepts Underlying Global Judgments in Dementia: Implications for Clinical Research—*F. Dahlke, A. Lohaus, and H. Gutzmann*

- 433** Self-Injurious Behavior in the Developmentally Disabled: Assessment Techniques—*Earl L. Loschen and Ossama T. Osman*
- 439** Self-Injurious Behavior in the Developmentally Disabled: Pharmacologic Treatment—*Ossama T. Osman and Earl L. Loschen*

Assessment Update: Trichotillomania

- 451** CSF 5-HIAA as a Predictor of Treatment Response in Trichotillomania—*Philip T. Ninan, Barbara O. Rothbaum, Mark Stipetic, Richard J. Lewine, and S. Craig Risch*
- 457** Rating the Severity of Trichotillomania: Methods and Problems—*Ronald M. Winchel, J. Sidney Jones, Avraham Molcho, Bruce Parsons, Barbara Stanley, and Michael Stanley*
- 463** The Psychiatric Institute Trichotillomania Scale (PITS)—*Ronald M. Winchel, J. Sidney Jones, Avraham Molcho, Bruce Parsons, Barbara Stanley, and Michael Stanley*

Basic Neuroscience Topics for the Clinical Investigator

- 477** The Role of Adenylate Cyclase in Neuropsychiatric Disease—*Julia B. Thilo and Philip W.J. Burnet*

**B1 Psychopharmacology—
A Recurring Bibliography**